Biomax Informatics AG announces that it has been selected as a consortium partner in the OncoTyrol project Center for Personalized Cancer Medicine, an Austrian COMET-program, which supports building up centers that are based on a top-level research program jointly formulated by science and industry.
This €28 million initiative focuses on translating genomic, proteomic and metabolomic research into innovative and individualized approaches for cancer diagnosis and treatment. It aims to achieve three primary goals: (1) to characterize the paradigm malignancies chronic myeloid and lymphocytic leukemia, breast and prostate cancer at the molecular level (2) to identify, verify and validate biomarkers for prediction of individual cancer risk, treatment response and outcome, and (3) to develop tailored therapies for cancer patients or cohorts that are most likely to benefit.
“This is an important milestone for Biomax and emphasizes our strategic commitment to provide innovative technology platforms to support workflows in personalized and translational medicine,” comments Dr. Klaus Heumann, CEO of Biomax Informatics.
“Translational science paradigms will have an increasing impact on discovery research and development processes in the life sciences industry. Our BioXM™ Knowledge Management Environment provides a platform that moves beyond traditional information limits to bridge discovery and clinical research departments,” he adds.
“The collaboration with Biomax Informatics will provide us with access to unique knowledge discovery and management technology and expertise. After an in-depth evaluation we concluded that the BioXM system, with its highly visual approach and outstanding data integration capabilities, is the backbone we need to make the visionary OncoTyrol project successful,” states Prof. Dr. Armin Graber, Head of the Institute for Bioinformatics at the University for Health Sciences, Medical Informatics and Technology (UMIT), and Area leader for bioinformatics and system biology in the OncoTyrol Initiative.